Live price temporarily unavailable.
Teleflex (TFX) is a Health Care company in the Russell 1000. Latest news and coverage below.
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $1.87B | $2.15B | $2.45B | $2.60B | $2.54B | $2.81B | $2.79B | $1.71B | $1.70B | $1.99B |
| Growth (year over year) | +3.2% | +14.9% | +14.1% | +6.0% | −2.2% | +10.7% | −0.7% | −38.6% | −0.8% | +17.2% |
| Gross profit | $996.2M | $1.17B | $1.30B | $1.41B | $1.32B | $1.55B | $1.53B | $1.04B | $1.04B | $1.12B |
| Gross margin | 53.3% | 54.6% | 53.2% | 54.3% | 52.2% | 55.2% | 54.9% | 60.7% | 61.0% | 56.2% |
| Operating income | $319.5M | $372.3M | $321.7M | $427.3M | $423.1M | $628.1M | $499.7M | $258.7M | $103.7M | $118.4M |
| Operating margin | 17.1% | 17.3% | 13.1% | 16.5% | 16.7% | 22.4% | 17.9% | 15.1% | 6.1% | 5.9% |
| Net income | $237.4M | $152.5M | $200.8M | $461.5M | $335.3M | $485.4M | $363.1M | $356.3M | $69.7M | −$905.6M |
| Net margin | 12.7% | 7.1% | 8.2% | 17.8% | 13.2% | 17.3% | 13.0% | 20.8% | 4.1% | −45.4% |
| EPS (diluted) | $4.98 | $3.27 | $4.29 | $9.80 | $7.09 | $10.23 | $7.68 | $7.53 | $1.48 | −$20.25 |
| Balance sheet | ||||||||||
| Cash and equivalents | $543.8M | $333.6M | $357.2M | $301.1M | $375.9M | $445.1M | $292.0M | $222.8M | $247.9M | $378.6M |
| Total assets | $3.89B | $6.18B | $6.28B | $6.31B | $7.15B | $6.87B | $6.93B | $7.53B | $7.10B | $6.95B |
| Total liabilities | $1.75B | $3.75B | $3.74B | $3.33B | $3.82B | $3.12B | $2.91B | $3.09B | $2.82B | $3.82B |
| Long-term debt | $850.3M | $2.16B | $2.07B | $1.86B | $2.38B | $1.74B | $1.62B | $1.73B | $1.56B | $2.54B |
| Shareholders' equity | $2.14B | $2.43B | $2.54B | $2.98B | $3.34B | $3.75B | $4.02B | $4.44B | $4.28B | $3.12B |
| Cash flow | ||||||||||
| Operating cash flow | $410.6M | $426.3M | $435.1M | $437.1M | $437.1M | $652.1M | $342.8M | $206.1M | $301.9M | $96.7M |
| Capital expenditure | $53.1M | $70.9M | $80.8M | $102.7M | $90.7M | $71.6M | $79.2M | $46.4M | $90.4M | $95.2M |
| Free cash flow | $357.5M | $355.4M | $354.3M | $334.4M | $346.4M | $580.5M | $263.6M | $159.7M | $211.4M | $1.45M |
| Dividends paid | $59.0M | $61.2M | $62.2M | $62.8M | $63.2M | $63.6M | $63.8M | $63.9M | $63.5M | $60.3M |
| Share buybacks | — | — | — | — | — | — | $0 | $0 | $200.0M | $300.0M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $426.2M | $442.0M | $414.3M | $442.5M | $566.9M | $569.0M | $548.3M | $570.3M |
| Growth (year over year) | −42.9% | — | +0.3% | +5.7% | +33.0% | +28.7% | +32.3% | +28.9% |
| Gross profit | $260.3M | $268.8M | $255.4M | $265.8M | $292.0M | $307.4M | $307.4M | $331.7M |
| Gross margin | 61.1% | 60.8% | 61.7% | 60.1% | 51.5% | 54.0% | 56.1% | 58.2% |
| Operating income | $72.0M | $52.4M | $75.8M | $91.1M | −$62.4M | $13.9M | $20.2M | $72.8M |
| Operating margin | 16.9% | 11.9% | 18.3% | 20.6% | −11.0% | 2.4% | 3.7% | 12.8% |
| Net income | $111.0M | −$136.7M | $95.0M | $122.6M | −$408.9M | −$714.3M | −$8.15M | $99.7M |
| Net margin | 26.0% | −30.9% | 22.9% | 27.7% | −72.1% | −125.5% | −1.5% | 17.5% |
| EPS (diluted) | $2.36 | −$2.89 | $2.07 | $2.77 | −$9.24 | −$15.85 | −$0.18 | $2.28 |
| Balance sheet | ||||||||
| Cash and equivalents | $243.2M | $247.9M | $284.1M | $253.7M | $354.0M | $378.6M | $309.4M | $300.2M |
| Total assets | $7.49B | $7.10B | $7.16B | $7.38B | $7.87B | $6.95B | $6.78B | $6.79B |
| Total liabilities | $3.00B | $2.82B | $3.07B | $3.13B | $4.05B | $3.82B | $3.70B | $3.88B |
| Long-term debt | $1.66B | $1.56B | $1.81B | $1.80B | $2.57B | $2.54B | $2.51B | $2.72B |
| Shareholders' equity | $4.48B | $4.28B | $4.10B | $4.24B | $3.82B | $3.12B | $3.08B | $2.90B |
| Cash flow | ||||||||
| Operating cash flow | $231.1M | −$133.7M | $27.7M | −$37.0M | $198.3M | −$92.3M | $46.7M | $91.9M |
| Capital expenditure | $21.2M | −$3.98M | $24.1M | $27.8M | $42.7M | $651.0K | $18.8M | $14.0M |
| Free cash flow | $209.9M | −$129.8M | $3.59M | −$64.8M | $155.6M | −$92.9M | $27.9M | $77.9M |
| Dividends paid | $15.8M | $15.7M | $15.2M | $15.0M | $15.0M | $15.0M | $15.1M | $14.8M |
| Share buybacks | $200.0M | $0 | $300.0M | $0 | $0 | $0 | $0 | $250.0M |
From Teleflex's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
Teleflex Incorporated, headquartered in Wayne, Pennsylvania, is an American provider of specialty medical devices for a range of procedures in critical care and surgery. Teleflex has annual revenues of $2.4 billion, operations in 40 countries, and more than 15,000 employees. By 2011, the company had substantially realigned to focus on its current business as a medical-device manufacturer, having undergone several years of active acquisitions and divestitures. Teleflex has been associated with Irish corporate tax avoidance tools. Teleflex's chief executive officer (CEO) is Jason Weidman ; Weidman is also the company's president.
No recent news mentioning Teleflex in our feed yet.